Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$103.23 USD
-0.20 (-0.19%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $103.06 -0.17 (-0.16%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Brokerage Reports
0 items in cart
Abbott Laboratories [ABT]
Reports for Purchase
Showing records 461 - 480 ( 527 total )
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Raising our estimates in light of strong Q3 CY11 results and upward revision to management?s guidance
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Third Quarter EPS Up 12%. ABT to Split Into Two Publicly-Traded Companies.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Raising our CY11 & CY12 estimates in light of upward revision to management?s guidance
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Dropping Coverage Due to Analyst Departure
Provider: WEDBUSH SECURITIES INC.
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Pharmaceuticals and Positive Currency Support Second Quarter Sales Growth
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Another Black Eye For An ABT Cholesterol Drug -- We See Modest Financial Risk, But Worries Are Likely To Hurt The Stock For The Time-Being
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
FDA Panel Recommends Tighter TriLipix Label- Vote Is as We Expected.
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Emerging markets strategy to be an important growth driver in near to medium term....Several late-stage projects in growing Pharma pipeline to boost longer term growth
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Emerging markets strategy to be an important growth driver in near to medium term....Several late-stage projects in growing Pharma pipeline to boost longer term growth
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
The Big Disconnect: Solid Results Gave No Boost to the Stock
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P